Targeting cellular factors is considered a promising approach to combat viral infection and overcome the resistance issue associated with direct-acting antiviral (DAA) drugs administration. In the context of drug repurposing strategies, we have previously explored the antiviral efficacy of the MEK i...
Treatment of infected cells with MEK1/2-inhibitor Zapnometinib (named ATR here in treatments) significantly changed gene expression after infection with SARS-CoV-2 virus.
